Overview
Cedric Bogaert is a co-founder and the chief executive of myNEO Therapeutics, a role he has held since January 2019. He is based in Ghent. Between January 2020 and January 2024 he was also a co-founder of Persomed. Before that he spent a year at Accenture, from January 2018 to January 2019, as a business and integration architecture senior analyst. He states expertise in entrepreneurship, business strategy and management.
He studied bio-engineering at Ghent University, taking a bachelor's degree in genetics from 2012 to 2015 and a master's degree in medicinal genetics from 2015 to 2017, with a period in 2015 at the University of Helsinki, also in bio-engineering and genetics. He took part in the Endless Frontier Lab accelerator programme at NYU Stern School of Business from October 2021 to June 2022, and in the Silicon Valley Entrepreneurship and Innovation programme at the Haas School of Business, University of California, Berkeley, in March 2023. He completed an Executive MBA at Vlerick Business School between September 2023 and June 2024.
Career history
In the news
- 𝗢𝗻𝗲 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲. 𝟭𝟰𝟱 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀. 𝗡𝗼 𝗹𝗼𝘀𝗲𝗿𝘀. On 19 August, Moderna and Merck announced positive Phase 3 results for their melanoma cancer vaccine. Moderna rose 177%, or $44B, in a day. Events like this are rare and analytically beautiful. One piece of news, one narrow window, nothing else competing for attention. About as close as this industry gets to a controlled experiment on biotech investors. I waited a week for the numbers to settle, then measured abnormal returns across 145 companies,
- A milestone years in the making. This month, the first patient received a new personalized therapeutic cancer vaccine for non-small cell lung cancer in the NEOVACC Phase I trial, led by The Clatterbridge Cancer Centre and the University of Liverpool. An important step for this program, which brought together government bodies, regulators, academic institutes and industry. Reaching patients is the ultimate validation of any discovery platform. We're happy to contribute with the ImmunoEngine platform, which identified and selected
- Another great achievement of Diether and the VIB. This is an important milestone in an exciting new strategic partnership between VIB and myNEO Therapeutics bringing novel breast cancer drugs to clinical stage development!
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.